Daihan Pharmaceutical Co.Ltd (023910) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩9.47 Billion ≈ $6.42 Million USD) by net assets (₩293.27 Billion ≈ $198.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Daihan Pharmaceutical Co.Ltd (023910) balance sheet quality index to measure how much of total assets are equity-financed.
Daihan Pharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Daihan Pharmaceutical Co.Ltd to evaluate the quality of earnings relative to operating cash generation.
Daihan Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kumho Petro Chemical Co Ltd
KO:011785
|
0.027x |
|
Hanmiglobal
KO:053690
|
-0.005x |
|
Powerlong Real Estate Holdings Limited
F:PW5
|
0.017x |
|
Jeld-Wen Holding Inc
NYSE:JELD
|
0.098x |
|
Ruentex Materials Co Ltd
TW:8463
|
0.186x |
|
Turbogen Chp
TA:TURB
|
1.208x |
|
SkyWorld Development Berhad
KLSE:5315
|
0.065x |
|
BICO Group AB
ST:BICO
|
-0.017x |
Annual Cash Flow Conversion Efficiency for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Daihan Pharmaceutical Co.Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩275.99 Billion ≈ $187.04 Million |
₩35.64 Billion ≈ $24.15 Million |
0.129x | -17.59% |
| 2023-12-31 | ₩247.97 Billion ≈ $168.05 Million |
₩38.86 Billion ≈ $26.34 Million |
0.157x | +21.80% |
| 2022-12-31 | ₩225.40 Billion ≈ $152.75 Million |
₩29.00 Billion ≈ $19.65 Million |
0.129x | -35.76% |
| 2021-12-31 | ₩202.81 Billion ≈ $137.44 Million |
₩40.62 Billion ≈ $27.53 Million |
0.200x | +8.35% |
| 2020-12-31 | ₩181.92 Billion ≈ $123.29 Million |
₩33.63 Billion ≈ $22.79 Million |
0.185x | -12.58% |
| 2019-12-31 | ₩166.78 Billion ≈ $113.02 Million |
₩35.26 Billion ≈ $23.90 Million |
0.211x | -33.96% |
| 2018-12-31 | ₩140.36 Billion ≈ $95.12 Million |
₩44.94 Billion ≈ $30.46 Million |
0.320x | +81.40% |
| 2017-12-31 | ₩115.88 Billion ≈ $78.53 Million |
₩20.45 Billion ≈ $13.86 Million |
0.177x | -41.25% |
| 2016-12-31 | ₩92.94 Billion ≈ $62.99 Million |
₩27.92 Billion ≈ $18.92 Million |
0.300x | +28.43% |
| 2015-12-31 | ₩76.84 Billion ≈ $52.07 Million |
₩17.98 Billion ≈ $12.18 Million |
0.234x | +58.11% |
| 2014-12-31 | ₩64.10 Billion ≈ $43.44 Million |
₩9.48 Billion ≈ $6.43 Million |
0.148x | -- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.